September 19, 2021

Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively.

Gross proceeds from the transaction totaled approximately $95.1 million.

PHILADELPHIA, September 02, 2021–(BUSINESS WIRE)–Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the closing of its previously announced business combination with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a special purpose acquisition company sponsored by Chardan Capital Markets (“Chardan”). Renovacor, Inc., the resulting combined company, expects to commence trading its common stock and public warrants under…

Read full article here: